Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

Table 4 Rates of alanine aminotransferase normalization, hepatitis B e antigen loss, hepatitis B e antigen seroconversion, and hepatitis B surface antigen loss at week 48

Outcome	ETV group (n = 30)	TAF group (n = 30)	P value
ALT normalization (%)	76.7	80.0	0.72
HBeAg loss (%)	25.0	33.3	0.51
HBeAg seroconversion (%)	8.3	33.3	0.04
HBsAg loss (%)	0.0	0.0	> 0.99

ETV: Entecavir; TAF: Tenofovir alafenamide; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.